Compare Colgate-Palmolive Company (CL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Summit Therapeutics Inc — how do they compare? Colgate-Palmolive Company trades at $92.56 (market cap $73.59B), while Summit Therapeutics Inc trades at $15.26 (market cap $12.06B). The key difference: Colgate-Palmolive Company is far larger — about 6.1× Summit Therapeutics Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CL | SMMT | |
|---|---|---|
Market Cap | $73.59B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $26.98 |
52-Week Low | $74.98 | $12.55 |
Enterprise Value | $80.07B | $11.39B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $92.66, down 0.53% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by strength in Latin America and Asia Pacific, though North American performance remains weak. Operating cash flow remains robust at $4.20 billion for 2025. The stock is trading below the consensus price target of $99.10.
The outlook is mixed, with strong profitability and consistent earnings beats offset by high valuation multiples and domestic market challenges. The primary opportunity lies in international growth and margin expansion, while risks include intense competition and reliance on emerging markets for growth.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
